These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 16678036

  • 1. Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation.
    Barnard JB, Thekkudan J, Richardson S, Bittar MN, Martyszczuck R, Hasan J, Khasati N, Keevil B, Yonan N.
    J Heart Lung Transplant; 2006 May; 25(5):564-8. PubMed ID: 16678036
    [Abstract] [Full Text] [Related]

  • 2. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
    Büchler M, Chadban S, Cole E, Midtvedt K, Thervet E, Prestele H, Keown P.
    Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
    [Abstract] [Full Text] [Related]

  • 3. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
    Hmiel SP, Canter C, Shepherd R, Lassa-Claxton S, Nadler M.
    Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
    [Abstract] [Full Text] [Related]

  • 4. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
    Akhlaghi F, Gonzalez L, Trull AK.
    J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
    [Abstract] [Full Text] [Related]

  • 5. Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study.
    Iversen M, Nilsson F, Sipponen J, Eiskjaer H, Mared L, Bergan S, Nyström U, Fagertun HE, Solbu D, Simonsen S.
    J Heart Lung Transplant; 2009 Sep; 28(9):919-26. PubMed ID: 19716045
    [Abstract] [Full Text] [Related]

  • 6. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes.
    Delgado DH, Rao V, Hamel J, Miriuka S, Cusimano RJ, Ross HJ.
    J Heart Lung Transplant; 2005 Sep; 24(9):1343-6. PubMed ID: 16143255
    [Abstract] [Full Text] [Related]

  • 7. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
    Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Hübler M, Abd El Rahman MY, Miera O, Ewert P, Weng Y, Wei H, Krüdewagen B, Hetzer R, Berger F.
    J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
    [Abstract] [Full Text] [Related]

  • 8. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
    Thervet E, Pfeffer P, Scolari MP, Toselli L, Pallardó LM, Chadban S, Pilmore H, Connolly J, Buchler M, Schena FP, Carreño CA, Dandavino R, Cole E.
    Transplantation; 2003 Sep 27; 76(6):903-8. PubMed ID: 14508352
    [Abstract] [Full Text] [Related]

  • 9. Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients.
    Davies RA, Veinot JP, Williams K, Haddad H, Baker A, Donaldson J, Pugliese C, Struthers C, Masters RG, Hendry PJ, Mesana T.
    Transplant Proc; 2007 Dec 27; 39(10):3334-9. PubMed ID: 18089382
    [Abstract] [Full Text] [Related]

  • 10. A randomized, controlled trial of C0- Vs C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients.
    Mathias HC, Ozalp F, Will MB, Borland W, Payne C, Kerr M, Lockhart J, Murday AJ.
    J Heart Lung Transplant; 2005 Dec 27; 24(12):2137-43. PubMed ID: 16364862
    [Abstract] [Full Text] [Related]

  • 11. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G, Grazi GL, Sanjuan F, Wu Y, Mühlbacher F, Samuel D, Friman S, Jones R, Cantisani G, Villamil F, Cillo U, Clavien PA, Klintmalm G, Otto G, Pollard S, McCormick PA.
    Liver Transpl; 2006 Oct 27; 12(10):1464-72. PubMed ID: 17004259
    [Abstract] [Full Text] [Related]

  • 12. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients.
    Caforio AL, Tona F, Piaserico S, Gambino A, Feltrin G, Fortina AB, Angelini A, Alaibac M, Bontorin M, Calzolari D, Peserico A, Thiene G, Iliceto S, Gerosa G.
    Transpl Int; 2005 Jan 27; 18(1):116-24. PubMed ID: 15612993
    [Abstract] [Full Text] [Related]

  • 13. Can cyclosporine blood level be reduced to half after heart transplantation?
    Wang SS, Chou NK, Chi NH, Huang SC, Wu IH, Wang CH, Yu HY, Chen YS, Tsao CI, Ko WJ, Shun CT.
    Transplant Proc; 2010 Apr 27; 42(3):930-3. PubMed ID: 20430207
    [Abstract] [Full Text] [Related]

  • 14. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-center pilot study.
    Kyllönen LE, Salmela KT.
    Transplantation; 2006 Apr 15; 81(7):1010-5. PubMed ID: 16612277
    [Abstract] [Full Text] [Related]

  • 15. Clinical outcomes and C2 cyclosporin monitoring in maintenance renal transplant recipients: 1 year follow-up study.
    Marcén R, Villafruela JJ, Pascual J, Teruel JL, Ocaña J, Tenorio MT, Burgos FJ, Ortuño J.
    Nephrol Dial Transplant; 2005 Apr 15; 20(4):803-10. PubMed ID: 15687111
    [Abstract] [Full Text] [Related]

  • 16. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E, Delucchi MA, Cano F, Valdebenito S, Castillo MC, Villegas R.
    Transplant Proc; 2005 Oct 15; 37(8):3354-7. PubMed ID: 16298594
    [Abstract] [Full Text] [Related]

  • 17. Target range maximum of cyclosporine blood concentration two hours post dose in stable liver transplant patients.
    Li J, Dahmen U, Beckebaum S, Cicinnati V, Valentin-Gamazo C, Frilling A, Malago M, Broelsch CE.
    Eur J Med Res; 2006 Apr 28; 11(4):139-45. PubMed ID: 16720277
    [Abstract] [Full Text] [Related]

  • 18. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy.
    Cantarovich M, Besner JG, Barkun JS, Elstein E, Loertscher R.
    Clin Transplant; 1998 Jun 28; 12(3):243-9. PubMed ID: 9642517
    [Abstract] [Full Text] [Related]

  • 19. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values.
    Troncoso P, Ortiz AM, Jara A, Vilches S.
    Transplant Proc; 2009 Jun 28; 41(1):127-30. PubMed ID: 19249495
    [Abstract] [Full Text] [Related]

  • 20. History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion.
    Cantarovich M, Barkun J, Giannetti N, Cecere R, Besner JG, Tchervenkov J.
    Transplant Proc; 2004 Mar 28; 36(2 Suppl):442S-447S. PubMed ID: 15041383
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.